Background: Recent study results demonstrate possible clinical benefit from adjuvant treatment with a standardized mistletoe (Viscum album) extract in patients with malignant melanoma.
INTRODUCTION

M
elanoma is a malignant tumor of epidermal melanocytes. In general, four types of melanoma are distinguished based on tumor localization and growth patterns, but only two of them are relevant for this case report and thus will be mentioned. Superficially spreading malignant melanoma (SSM) is characterized by primarily horizontal tumor growth of an intraepidermal population of epitheloidal melanoma cells, showing a lead shot-like dis-tribution (pagetoid growth pattern). Nodular melanoma (NM) shows a basically nodular growth pattern in clinically normal surrounding skin, missing on a tangible phase of radial growth. 1 In general, the prognosis depends on the thickness of the tumor. Prognosis depends on the stage at diagnosis and patients with melanoma require close follow-up because they are at risk for recurrence and diagnosis of a second primary tumor. 2 Studies show that total survival is inversely correlated to tumor thickness. 3 Numerous examples such as spontaneous remissions and extremely aggressive courses in immunocompromised patients confirm the role of immunologic factors for tumor progression in this type of neoplasia. 4, 5 The use of mistletoe (Viscum album) extracts is currently an important part of complementary tumor therapy. It was observed that extracts from mistletoe show antimetastatic properties in close connection with stimulation of relevant parameters of immunogenicity (e.g., liberation of cytokines). It must be surmised that treatment with standardized extracts from mistletoe should be able to prevent the formation of metastases and the further distribution of malignant cells. 6 Recently, an increase in adjusted tumor-dependent survival compared to untreated patients was found by a multicenter comparative epidemiologic cohort study from Germany and Switzerland. 7 This case report is about a patient with malignant melanoma who was treated successfully with standardized extract from mistletoe as long-term therapy.
PATIENT AND METHOD
Patient
We describe the case of a 68-year-old man who had been diagnosed with SSM at the right upper part arm in 1992 when he was 55. A detailed noncancer anamnesis can just be reduced to sport accidents and childhood diseases. Besides benign prostatic hyperplasia with early symptoms of trabeculated bladder, no other comorbidities were present at the time of first diagnosis. Neither comorbidities nor comedication (also noncancer) were reported from the patient.
Standardized extract of mistletoe
The drug administered in this patient's therapy was Iscador ® M, a formulation of standardized mistletoe extract manufactured by Weleda AG, CH-Arlesheim, Switzerland.
Treatment course
In June 1992, histopathologic findings after skin excision at the upper part of the right arm confirmed a stage IA SSM (with low-grade infiltration of the papillary dermis, Clark level II, pT1, N0, M0, Breslow index 0.375 mm).
In November 1999, another melanoma was surgically re- 
DISCUSSION
In this case presentation of a 68-year-old patient with metastatic melanoma, complete tumor remission was achieved with twice-weekly subcutaneous administration of Iscador M. The remission was established and confirmed by KIRSCHultrasound imaging. No other systemic treatments or chemotherapy had been administered before Iscador M.
Considering these circumstances, it stands to reason that the observed complete remission was indeed induced by treatment with Iscador M.
It must be stressed that the observed regression of the liver lesion was achieved using only a low drug dose. The clinical improvement initiated with Iscador M is in accordance with results of our earlier pilot study that observed several cases of tumor regression under low-dose Iscador. 8 Obviously, there are data that should be studied carefully and generalization should be avoided. 9 On the other hand, there are trials that show benefit. 7 The fact that mistletoe is used to a considerable extent implies that much data are available about experience with this extract. [10] [11] [12] [13] If individual case reports are methodically and systematically correctly documented, however, they can probably provide important knowledge about the effects of a therapy. [14] [15] [16] One weak aspect in this case report is the type of imaging used to follow the lesion. Although modern ultrasound sonography has become highly sensitive, the power of this method still greatly depends on the experience of the investigator.
Unfortunately, independent confirmation of the complete tumor remission with other imaging methods such as CT or abdominal magnetic resonance imaging was impossible because of the patient's unwillingness to undergo these tests.
CONCLUSIONS
Regular subcutaneous postoperative treatment with Iscador M has in this case proved to be a very effective, welltolerated, and successful means in treating metastatic melanoma, leading to complete remission.
This single case report should be encouraging for stimulating further investigation of effectiveness and tolerability of standardized mistletoe extracts for the treatment of malignant melanoma in the framework of carefully designed Good Clinical Practice studies.
